DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Posição atual:
>
> This Story


Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Emory University opens first proton therapy center in Georgia 28th PT center in the U.S.

Elekta Unity MR-linac gains FDA 510(k) clearance Simultaneously delivers radiation dose and visualization of tumors

Dr. Hermann Requardt United Imaging Healthcare appoints senior scientific advisor

Patient denied proton therapy dies, family received $25 million in court Points to the need for greater treatment coverage for certain cancer patients

Microbeam radiation therapy could lead to single session treatments Healthy cells tolerate treatment while tumors lose structure

CMS to unveil mandatory payment model for radiation oncology Part of determining approach that saves more and offers greater quality

European report says radiotherapy 'undervalued' and needing 'greater investment' Equipment shortages, lack of investment, training variations

ViewRay to supply UK's GenesisCare with country's first MRIdian systems Providing soft-tissue imaging in real time and better tumor targeting

Accuray showcases software upgrades for CyberKnife and Radixact at ASTRO Allows for 40 percent faster treatment delivery

Precision cancer care with proton and radiation oncology Some of the latest systems and software entering the market

For this cancer, proton therapy is no better than IMRT

por John R. Fischer , Staff Reporter
Proton therapy (PT) may not be a safer bet compared to conventional radiation when it comes to lowering toxicity associated with non-small cell lung cancer (NSCLC).

At least that’s what researchers at the University of Texas MD Anderson Cancer Center and Massachusetts General Hospital say in a new study comparing dose distribution of 3-D passive scattering proton therapy (PT) and intensity-modulated radiation therapy (IMRT), finding no decline in risks, such as radiation pneumonitis, when using the former type of treatment. Their findings were published in the Journal of Clinical Oncology.

Story Continues Below Advertisement

Dunlee announces the relaunch of DA135 CT/e, DA165NP and Akron tubes

Dunlee announces the return of the DA135 CT/e, DA165NP, S532B and S532Q(known as the Akron tubes) CT Replacement tubes, making its full portfolio of CT tubes for GE and Siemens CT scanners available once again.Click to learn more



“There is no doubt that there is dosimetric advantage in protons compared with photons. Whether the dosimetric advantage will translated to clinical benefit or not depends on many factors including how best use this new form of radiation," Dr. Zhongxing Liao, the lead author of the study and a professor of Radiation Oncology at the University of Texas MD Anderson Cancer Center, told HCB News. "Our trial showed that, using an outdated way, passively scattered proton beam or 3-D conformal proton, to deliver proton, we were not able to realize the dosimetric advantage of the proton on lung; therefore, we did not reduce radiation pneumonitis."

The presumption that proton therapy is superior to conventional radiation due to its more-targeted form of delivery have led some to conclude that randomized trials comparing the two are unnecessary, inappropriate and unethical.

Researchers tested this hypothesis in a Bayesian trial in which 149 patients with inoperable NSCLC were randomly selected to undergo IMRT or PSPT with the objective being to determine if PSPT patients showed a lower risk of grade ≥ 3 RP or local failure (LF).

PSPT was found to expose less lung tissue at 5-10 GY (RBE) doses but more at doses of 20 GY (RBE) or higher. No benefits in grade ≥ 3 RP or LF were found in these patients with locally advanced NSCLC.

A one-year follow-up found the PSPT group had a 10.5 percent rate of ≥ 3 RP compared with 6.5 percent of IMRT patients.

Rates of LF were 10.9 percent at one year for patients who underwent IMRT, compared to 10.5 percent of PSPT patients. Combined RP and LF rates at one year were 17.4 percent and 21.1 percent following IMRT and PSPT, respectively.

Though not the main focus, median survival for PSPT patients was 26.1 months and for IMRT, 29.5.

The findings here could make many skeptical of growth predictions for the proton therapy market, which is expected to almost double in value by 2022. They also contrast with a recent study that compared PT and IMRT in the treatment of prostate cancer, finding higher survival rates and less complications induced by radiation exposure among patients who underwent PT.

“The trial tells us that, when investing for proton centers, one needs to be aware of the issues encountered in our trial and be prepared to address them," said Liao. "Adequate engineering, physics, clinical and research support is critical to ensure the success of the proton centers.”

Despite these results, the use of PSPT was found to reduce heart exposure to radiation at levels between 5 and 80 Gy, as well as heart volume, with its impact on cardiac toxicity and overall survival currently under study.

Sparing the heart for overall survival is currently being evaluated in a phase III randomized lung trial that will provide evidence on the use of proton therapy for lung cancer, while a phase II study is comparing the effects of IMRT to the next-generation proton technique intensity-modulated proton therapy. Both will help in providing more information on the comparisons between proton therapy and photon treatments.

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente a Sua Perceção da Marca
Leilões + Vendas Privadas
Comece
O mais melhor preço
Comprar Equipamento/Peças
Encontre
O preço o mais baixo
Notícia diária
Leia
A notícia a mais atrasada
Diretório
Browse tudo
DOTmed Usuários
Ética no DOTmed
Veja o nosso
Programa das éticas
O ouro parte o programa do vendedor
Receba PH
Pedidos
Programa do negociante do serviço do ouro
Receba RFP/PS
Pedidos
Fornecedores de Healthcare
Veja tudo
Ferramentas de HCP
Trabalhos/Treinamento
Achado/suficiência
Um trabalho
Parts Hunter +EasyPay
Comece as peças
Citações
Certificado recentemente
Vista recentemente
Usuários certificados
Recentemente Rated
Vista recentemente
Usuários certificados
Central Rental
Equipamento do aluguel
Para menos
Vender Equipamentos/Peças
Comece
A maioria de dinheiro
Preste serviços de manutenção ao Forum dos técnicos
Ajuda do achado
E conselho
Simples RFP
Comece o equipamento
Citações
Mostra de comércio virtual
Serviço do achado
Para o equipamento
O acesso e o uso deste local são sujeitos aos termos e às condições do nosso OBSERVAÇÃO LEGAL & OBSERVAÇÃO DA PRIVACIDADE
Propriedade de e proprietário DOTmeda .com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
TODOS OS DIREITOS RESERVADOS